Unlike mRNA vaccines — which only produce the spike protein necessary for immune response as long as the mRNA persists — saRNA vaccines are engineered to create copies of themselves and the proteins they encode. This "biological printing press" could theoretically amplify the vaccine’s presence and multiply its effects within the body indefinitely.
According to CSL, the vaccine demonstrated higher immunogenicity and a favorable safety profile compared to original mRNA vaccines during clinical trials. However, independent vaccine researchers are voicing serious concerns regarding the safety and efficacy of this untested technology.
Dr. Nicolas Hulscher stated, “These products are completely new. There is absolutely no long-term safety data on them.” In trials for ARCT-154, he noted a near 90 percent adverse event rate after the first dose, with clinicians observing significant systemic reactions in participants. Serious and medically-attended adverse events were only recorded from Day 1 to Day 92.
Karina Acevedo Whitehouse, a microbiology professor, emphasized the lack of comprehensive studies on the long-term effects of self-amplifying mRNA technology. She pointed out that there are no assessments of potential cellular transformations, including the risks of cancerous mutations or inflammatory responses. “We simply do not know what the consequences could be,” she warned.
“There have also been no studies conducted on trans-generational
effects — for instance, teratogenicity [birth defects] — of
self-amplifying mRNA injections,” she said. “We simply do not know what
the consequences could be.”...<<<Read More>>>...